Pulmatrix Acquires Eos SENOLYTIX in Definitive Merger to Advance Mitochondrial Therapies

Pulmatrix to Merge with Cullgen to Form Nasdaq-Listed Company Focused on Targeted Protein Degradation

November 13, 2024

Biotechnology

Pulmatrix announced a proposed merger with Cullgen to create a Nasdaq-listed biopharmaceutical company focused on targeted protein degradation, including three degrader programs in or about to begin Phase 1 clinical trials. The combined company is expected to operate as Cullgen Inc. headquartered in San Diego, California, with closing expected by end of March 2025 subject to approvals. As part of the merger agreement, Pulmatrix plans to divest certain assets, and Pulmatrix stockholders are expected to receive a special cash dividend contingent on net cash at closing.

PD Theranostics (Lucius Partners) Merges with Ovation.io

September 5, 2024

Biotechnology

PD Theranostics, a Lucius Partners portfolio company, has completed a merger with Ovation.io to create a multiomics data company that combines Ovation's population-scale biobank with PDTx's high-dimensional imaging and multiomic platform. The combined business will link sequencing, imaging, and longitudinal clinical data to accelerate biomarker and target discovery for drug development and clinical research.

Electromedical Products International Acquires Pulvinar Neuro

March 17, 2022

Medical Devices

Electromedical Products International (EPI) has acquired Pulvinar Neuro, a research-oriented medical device company focused on closed-loop neuromodulation and digital therapeutics. The deal expands EPI's scientific and research capabilities to accelerate development and commercialization of Pulvinar's transcranial alternating current stimulation (tACS), individualized feedback stimulation, and cloud-enabled digital therapeutics.

Novartis to Acquire MorphoSys in $2.9 Billion Deal

February 7, 2024

Pharmaceuticals

Novartis agreed to a voluntary public takeover offer to acquire MorphoSys AG for €68 per share, valuing the deal at about €2.7 billion (reported as $2.9 billion). The acquisition is intended to expand and complement Novartis’ oncology pipeline, including pelabresib (CPI-0610) and tulmimetostat (CPI-0209).

Altos Labs Acquires Dorian Therapeutics

May 23, 2025

Biotechnology

Altos Labs has acquired Stanford spinout Dorian Therapeutics, a preclinical senotherapeutics startup developing small-molecule "senoblockers." Financial terms were not disclosed; Altos said the deal broadens its cellular rejuvenation capabilities by adding Dorian’s epigenetic senescence-targeting technology and preclinical programs in lung fibrosis and osteoarthritis.

Genmab A/S Acquires Merus N.V. via Tender Offer

December 12, 2025

Biotechnology

Genmab A/S, through its wholly owned purchaser Genmab Holding II B.V., completed a tender offer to acquire outstanding common shares of Merus N.V. for $97.00 per share and commenced a subsequent offering period. The acquisition adds Merus' lead late‑stage oncology asset petosemtamab to Genmab's portfolio, expanding its antibody therapeutics pipeline and expected to be accretive to EBITDA by 2029.